In this study, we investigated the therapeutic potential of leukotriene inhibition with montelukast and zileuton in a murine model of LPS‐induced ARDS, focusing on their effects on PMN migration, cytokine release, receptor expression, and ERK1/2 expression. The gene discussed is MAPK3; the disease is acute respiratory distress syndrome.